Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899224 | 0.96 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL30771002 | 0.96 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL30858461 | 0.96 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL1582585 | 0.93 | CYP3A4 (0.39) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL1581988 | 0.91 | CYP3A4 (0.35) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL13456274 | 0.91 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL34871 | 0.91 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL301069 | 0.91 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| SCHEMBL301035 | 0.91 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 | |
| Lithium SCHEMBL30167974 | 0.91 | CYP3A4 (0.38) | CYP3A4TDP1GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622973-A1 | INHIBITORS OF ROCK2 | Graviton Bioscience BV (NL) | 2025-10-01 | — | — | EP | disclosed |
| EP-4562000-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119604496-A | ROCK2 inhibitors | 格雷威顿生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514466-A1 | INHIBITORS OF ROCK2 | Graviton Bioscience BV (NL) | 2025-03-05 | — | — | EP | disclosed |
| CN-114746408-B | Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors | 豪夫迈·罗氏有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-112041998-B | Composition, organic photoelectric device and display device | 三星SDI株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4291559-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Tango Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023209692-A1 | INHIBITORS OF ROCK2 | GRAVITON BIOSCIENCE BV (NL) | 2023-11-02 | — | — | WO | disclosed |
| CN-111278818-B | BTK inhibitor compounds | 伊莱利利公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115715293-A | Heterocyclic compound and organic electroluminescent device comprising the same | 出光兴产株式会社 | 2023-02-24 | — | — | CN | disclosed |
| CN-115433161-A | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022240879-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022174184-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | TANGO THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CYP3A4 3871/4885TDP1 3388/4885GAA 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.